[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13.
|
[3]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2015) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[4]
|
高梓茗, 徐惠绵. 胃癌精准外科治疗的研究新进展[J]. 中华医学信息导报, 2021, 36(1): 7-8.
https://doi.org/10.3760/cma.j.issn.1000-8039.2021.01.106
|
[5]
|
曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 145-149.
|
[6]
|
Lauwers, G.Y., Mullen, J.T., Chelcun Schreiber, K.E. and Chung, D.V. (2014) Familial Gastric Cancers: A Review with Focus on Hereditary Diffuse Gastric Cancer Syndrome. Pathology Case Reviews, 19, 66-73.
https://doi.org/10.1097/PCR.0000000000000030
|
[7]
|
Boland, C.R. and Yurgelun, M.B. (2017) Historical Per-spective on Familial Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology, 3, 192-200. https://doi.org/10.1016/j.jcmgh.2016.12.003
|
[8]
|
Pinheiro, H., Oliveira, C., Seruca, R. and Carneiro, F. (2014) Hereditary Diffuse Gastric Cancer—Pathophysiology and Clinical Management. Best Practice & Research Clinical Gas-troenterology, 28, 1055-1068.
https://doi.org/10.1016/j.bpg.2014.09.007
|
[9]
|
Kim, J., Cho, Y.A., Choi, W.J. and Jeong, S.H. (2014) Gene-Diet Interactions in Gastric Cancer Risk: A Systematic Review. World Journal of Gastroenterology, 20, 9600-9610. https://doi.org/10.3748/wjg.v20.i28.9600
|
[10]
|
Moy, K.A., Fan, Y., Wang, R., et al. (2010) Alcohol and Tobacco Use in Relation to Gastric Cancer: A Prospective Study of Men in Shanghai, China. Cancer Epidemiology Biomarkers & Prevention, 19, 2287-2297.
https://doi.org/10.1158/1055-9965.EPI-10-0362
|
[11]
|
Sauid, I. and Lois, N. (2015) Helicobacter pylori and Gastric Cancer: A State of the Art Review. Shaheed Beheshti University of Medical Sciences, 8, S6-S14.
|
[12]
|
Khatoon, J., Rai, R.P. and Prasad, K.N. (2016) Role of Helicobacter pylori in Gastric Cancer: Updates. World Journal of Gastrointestinal Oncology, 8, 147-158. https://doi.org/10.4251/wjgo.v8.i2.147
|
[13]
|
中国抗癌协会胃癌专业委员会. CACA胃癌整合诊治指南(精简版) [J]. 中国肿瘤临床, 2022, 49(14): 703-710.
|
[14]
|
国家癌症中心, 国家肿瘤质控中心胃癌质控专家委员会. 中国胃癌规范诊疗质量控制指标(2022版) [J]. 中华肿瘤杂志, 2022, 44(10): 997-1002.
|
[15]
|
中华医学会消化内镜学分会病理学协作组. 中国消化内镜活组织检查与病理学检查规范专家共识(草案) [J]. 中华消化内镜杂志, 2014(9): 481-485.
|
[16]
|
Bornschein, J., Quante, M. and Jansen, M. (2021) The Complexity of Cancer Origins at the Gastro-Oesophageal Junction. Best Practice & Research Clinical Gastroenterology, 50-51, Article ID: 101729.
https://doi.org/10.1016/j.bpg.2021.101729
|
[17]
|
国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018年版) [J]. 中华胃肠外科杂志, 2018, 21(9): 961-975.
|
[18]
|
Kim, S.T., Cristescu, R., Bass, A.J., et al. (2018) Comprehensive Molecular Characterization of Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer. Nature Medicine, 24, 1449-1458.
https://doi.org/10.1038/s41591-018-0101-z
|
[19]
|
中华人民共和国国家卫生和计划生育委员会. 胃癌规范化诊疗指南(试行) [J]. 中国医学前沿杂志(电子版), 2013(8): 56-63.
|
[20]
|
张成海, 武爱文, 李子禹, 等. 进展期胃癌脾门区淋巴结转移及其清扫方式[J]. 中华胃肠外科杂志, 2011, 14(8): 589-592.
|
[21]
|
焦旭光, 梁寒, 邓靖宇, 等. 进展期胃癌第14v组淋巴结转移的危险因素分析[J]. 中华消化外科杂志, 2014, 13(1): 30-33.
|
[22]
|
Eom, B.W., Joo, J., Kim, Y.W., et al. (2014) Improved Survival after Adding Dissection of the Superior Mesenteric Vein Lymph Node (14v) to Standard D2 Gastrectomy for Advanced Distal Gastric Cancer. Surgery, 155, 408-416.
https://doi.org/10.1016/j.surg.2013.08.019
|
[23]
|
Wu, L., Zhang, C., Liang, Y., et al. (2018) Risk Factors for Metas-tasis to No.14v Lymph Node and Prognostic Value of 14v Status for Gastric Cancer Patients after Surgery. Japanese Journal of Clinical Oncology, 48, 335-342.
https://doi.org/10.1093/jjco/hyy006
|
[24]
|
Kurokawa,Y., Takeuchi, H., Doki, Y., et al. (2021) Mapping of Lymph Node Metastasis from Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Annals of Sur-gery, 274, 120-127.
https://doi.org/10.1097/SLA.0000000000003499
|
[25]
|
李双喜, 李子禹. 食管胃结合部腺癌腹腔镜手术的下纵隔淋巴结清扫边界及质量控制[J]. 中华胃肠外科杂志, 2022, 25(2): 120-123.
|
[26]
|
Ohira, M., Toyokawa, T., Sa-kurai, K., et al. (2016) Current Status in Remnant Gastric Cancer after Distal Gastrectomy. World Journal of Gastroen-terolog, 22, 2424-2433. https://doi.org/10.3748/wjg.v22.i8.2424
|
[27]
|
Yoshida, K., Kodera, Y., Kochi, M., et al. (2019) Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients with Stage III Gastric Cancer: In-terim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 37, 1296-1304. https://doi.org/10.1200/JCO.18.01138
|
[28]
|
Park, S.H., Lim, D.H., Sohn, T.S., et al. (2021) A Randomized Phase III Trial Comparing Adjuvant Single-Agent S1, S-1 with Oxaliplatin, and Postoperative Chemoradiation with S-1 and Oxaliplatin in Patients with Node-Positive Gastric Cancer after D2 Resection: The ARTIST 2 Trial. Annals of Oncology, 32, 368-374.
https://doi.org/10.1016/j.annonc.2020.11.017
|
[29]
|
Lee, J., Lim, D.H., Kim, S., et al. (2012) Phase III Trial Com-paring Capecitabine plus Cisplatin versus Capecitabine plus Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with D2 Lymph Node Dissection: The ARTIST Trial. Journal of Clinical Oncology, 30, 268-273. https://doi.org/10.1200/JCO.2011.39.1953
|
[30]
|
Bang, Y.J., Kim, Y.W., Yang, H.K., et al. (2012) Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial. The Lancet, 379, 315-321.
https://doi.org/10.1016/S0140-6736(11)61873-4
|
[31]
|
Kang, Y.K., Yook, J.H., Park, Y.K., et al. (2021) PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 39, 2903-2913. https://doi.org/10.1200/JCO.20.02914
|
[32]
|
Al-Batran, S.E., Homann, N., Pauligk, C., et al. (2019) Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1
|
[33]
|
Wagner, A.D., Grabsch, H.I., Mauer, M., et al. (2019) EORTC-1203-GITCG—The “INNOVATION”-Trial: Effect of Chemotherapy Alone versus Chemotherapy plus Trastuzumab, versus Chemotherapy plus Trastuzumab plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma on Pathologic Response Rate: A Randomized Phase II-Intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group. BMC Cancer, 19, Article No. 494.
https://doi.org/10.1186/s12885-019-5675-4
|
[34]
|
Wilke, H., Muro, K., Van Cutsem, E., et al. (2014) Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gas-tro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. The Lancet On-cology, 15, 1224-1235.
https://doi.org/10.1016/S1470-2045(14)70420-6
|
[35]
|
Xu, R.H., Zhang, Y., Pan, H., et al. (2021) Efficacy and Safety of Weekly Paclitaxel with or without Ramucirumab as Second-Line Therapy for the Treatment of Advanced Gas-tric or Gastroesophageal Junction Adenocarcinoma (RAINBOW-Asia): A Randomised, Multicentre, Double-Blind, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 6, 1015-1024. https://doi.org/10.1016/S2468-1253(21)00313-7
|
[36]
|
Peng, Z., Liu, T., Wei, J., et al. (2021) Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2-Overexpressing, Locally Advanced or Metastat-ic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study. Cancer Communications, 41, 1173-1182. https://doi.org/10.1002/cac2.12214
|
[37]
|
Pang, X., Wei, W., Leng, W., et al. (2014) Radiotherapy for Gastric Can-cer: A Systematic Review and Meta-Analysis. Tumour Biology, 35, 387-396. https://doi.org/10.1007/s13277-013-1054-y
|
[38]
|
Hiramoto, S., Kikuchi, A., Tetsuso, H., et al. (2018) Efficacy of Palliative Radiotherapy and Chemo-Radiotherapy for Unresectable Gastric Cancer Demonstrating Bleeding and Obstruc-tion. International Journal of Clinical Oncology, 23, 1090-1094. https://doi.org/10.1007/s10147-018-1317-0
|
[39]
|
石汉平. 营养治疗的疗效评价[J]. 肿瘤代谢与营养电子杂志, 2017, 4(4): 364-370.
|
[40]
|
Braga, M., Ljungqvist, O., Soeters, P., et al. (2009) ESPEN Guidelines on Parenteral Nutrition: Surgery. Clinical Nutrition, 28, 378-386. https://doi.org/10.1016/j.clnu.2009.04.002
|
[41]
|
Liu, X.X., Jiang, Z.W., Wang, Z.M. and Li, J.S. (2010) Multimodal Optimization of Surgical Care Shows Beneficial Outcome in Gastrectomy Surgery. Journal of Parenteral and Enteral Nutrition, 34, 313-321.
https://doi.org/10.1177/0148607110362583
|